CN1909908A - 用于治疗蛋白激酶依赖性疾病的吡唑并[1,5－a]嘧啶－7－基－胺衍生物 - Google Patents

用于治疗蛋白激酶依赖性疾病的吡唑并[1,5－a]嘧啶－7－基－胺衍生物 Download PDF

Info

Publication number: CN1909908A
Authority: CN; China
Prior art keywords: phenyl; methyl; pyrazolo; pyrimidin; ylamine
Prior art date: 2004-01-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CNA2005800030379A

Other languages

English (en)

Chinese (zh)

Inventor

G·博尔德

A·弗勒尔斯海默

P·菲雷

P·因巴赫

升谷敬一

J·舍普费尔

G·马蒂尼-巴伦

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-22

Filing date

2005-01-21

Publication date

2007-02-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34807167&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1909908(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-01-21 Application filed by Novartis AG filed Critical Novartis AG

2007-02-07 Publication of CN1909908A publication Critical patent/CN1909908A/zh

Status Pending legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Oncology (AREA)
Transplantation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CNA2005800030379A 2004-01-22 2005-01-21 用于治疗蛋白激酶依赖性疾病的吡唑并[1,5－a]嘧啶－7－基－胺衍生物 Pending CN1909908A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US53822004P	2004-01-22	2004-01-22
US60/538,220		2004-01-22

Publications (1)

Publication Number	Publication Date
CN1909908A true CN1909908A (zh)	2007-02-07

Family

ID=34807167

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CNA2005800030379A Pending CN1909908A (zh)	2004-01-22	2005-01-21	用于治疗蛋白激酶依赖性疾病的吡唑并[1,5－a]嘧啶－7－基－胺衍生物

Country Status (17)

Country	Link
EP (1)	EP1708710A1 (es)
JP (1)	JP2007519662A (es)
KR (1)	KR20070009546A (es)
CN (1)	CN1909908A (es)
AR (1)	AR049769A1 (es)
AU (1)	AU2005205915B2 (es)
BR (1)	BRPI0507071A (es)
CA (1)	CA2552885A1 (es)
EC (1)	ECSP066718A (es)
IL (1)	IL176737A0 (es)
MA (1)	MA28400B1 (es)
NO (1)	NO20063758L (es)
PE (1)	PE20051089A1 (es)
RU (1)	RU2006130003A (es)
TN (1)	TNSN06226A1 (es)
TW (1)	TW200528103A (es)
WO (1)	WO2005070431A1 (es)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102918043A (zh) *	2010-02-19	2013-02-06	诺瓦提斯公司	作为cdk4/6抑制剂的吡咯并嘧啶化合物
CN103097380A (zh) *	2010-08-09	2013-05-08	株式会社创药分子设计	酪蛋白激酶1δ 及酪蛋白激酶1ε 抑制剂
CN105906630A (zh) *	2015-04-06	2016-08-31	四川百利药业有限责任公司	用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物
CN106588893A (zh) *	2016-12-01	2017-04-26	北京万全德众医药生物技术有限公司	维拉佐酮双氧化物的制备
CN109836428A (zh) *	2019-02-27	2019-06-04	华东师范大学	具有免疫抑制活性的吡唑[4,3-d]嘧啶衍生物及用途
CN114751910A (zh) *	2022-05-17	2022-07-15	重庆文理学院	一种可诱导细胞巨泡式死亡的化合物及其制备方法和应用
CN117843642A (zh) *	2022-10-09	2024-04-09	麦科萨药业(苏州)有限公司	一种双官能化合物及其用途

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7605155B2 (en) *	2002-09-04	2009-10-20	Schering Corporation	Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7196078B2 (en)	2002-09-04	2007-03-27	Schering Corpoartion	Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) *	2002-09-04	2009-07-21	Schering Corporation	Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
GB0515026D0 (en) *	2005-07-21	2005-08-31	Novartis Ag	Organic compounds
US20070082900A1 (en) *	2005-10-06	2007-04-12	Schering Corporation	Methods for inhibiting protein kinases
CN101321760A (zh) *	2005-10-06	2008-12-10	先灵公司	作为蛋白激酶抑制剂的吡唑并嘧啶
SI2495016T1 (sl)	2005-12-23	2020-04-30	Ariad Pharmaceuticals, Inc.	Biciklične heteroarilne spojine
MX2008011430A (es) *	2006-03-08	2008-09-18	Novartis Ag	Uso de derivados de pirazolo-[1,5a]-pirimidin-7-il-amina en el tratamiento de trastornos neurologicos.
WO2007109183A2 (en) *	2006-03-20	2007-09-27	Novartis Ag	Mutations and polymorphisms of fms-related tyrosine kinase 1
GB0606805D0 (en) *	2006-04-04	2006-05-17	Novartis Ag	Organic compounds
GB0606804D0 (en) *	2006-04-04	2006-05-17	Novartis Ag	Organic Compounds
EP2074127A1 (en) *	2006-09-28	2009-07-01	Novartis AG	Pyrazolo [1, 5-a]pyrimidine derivatives and their therapeutic use
WO2008037477A1 (en)	2006-09-29	2008-04-03	Novartis Ag	Pyrazolopyrimidines as p13k lipid kinase inhibitors
EP1918291A1 (en) *	2006-10-30	2008-05-07	Novartis AG	3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators
JP5198562B2 (ja) *	2007-06-07	2013-05-15	メルク・シャープ・アンド・ドーム・コーポレーション	置換−３−アミノピラゾールの合成
US8591943B2 (en)	2009-04-09	2013-11-26	Merck Sharp & Dohme Corp.	Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
JP2013506669A (ja)	2009-09-30	2013-02-28	メルク・シャープ・アンド・ドーム・コーポレーション	Ｅｒｋ阻害剤である新規化合物
NZ604708A (en)	2010-05-20	2015-05-29	Array Biopharma Inc	Macrocyclic compounds as trk kinase inhibitors
WO2012023143A1 (en)	2010-08-19	2012-02-23	E. I. Du Pont De Nemours And Company	Fungicidal pyrazoles
US9242981B2 (en)	2010-09-16	2016-01-26	Merck Sharp & Dohme Corp.	Fused pyrazole derivatives as novel ERK inhibitors
KR101404151B1 (ko) *	2011-11-25	2014-06-05	가톨릭대학교 산학협력단	안과 질환의 예방 및 치료용 약학 조성물
BR112018000808A2 (pt)	2015-07-16	2018-09-04	Array Biopharma Inc	compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
TWI752098B (zh)	2016-10-10	2022-01-11	美商亞雷生物製藥股份有限公司	作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh)	2016-10-10	2020-09-11	美商亞雷生物製藥股份有限公司	作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
US11168090B2 (en)	2017-01-18	2021-11-09	Array Biopharma Inc.	Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018136663A1 (en)	2017-01-18	2018-07-26	Array Biopharma, Inc.	Ret inhibitors
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI812649B (zh)	2017-10-10	2023-08-21	美商絡速藥業公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh)	2017-10-10	2023-02-01	美商亞雷生物製藥股份有限公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
EP3740491A1 (en)	2018-01-18	2020-11-25	Array Biopharma, Inc.	Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143991A1 (en)	2018-01-18	2019-07-25	Array Biopharma Inc.	SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
CN111615514B (zh)	2018-01-18	2022-10-11	奥瑞生物药品公司	作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
EP3746071A4 (en)	2018-01-29	2021-09-01	Merck Patent GmbH	GCN2 INHIBITORS AND THEIR USES
KR20200116481A (ko) *	2018-01-29	2020-10-12	메르크 파텐트 게엠베하	Gcn2 억제제 및 이의 용도
EP3849986B1 (en)	2018-09-10	2022-06-08	Array Biopharma, Inc.	Fused heterocyclic compounds as ret kinase inhibitors
US20210008173A1 (en) *	2019-07-10	2021-01-14	Musc Foundation For Research Development	Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
KR102598203B1 (ko)	2019-11-25	2023-11-03	암젠 인크	델타-5 불포화효소 억제제로서의 헤테로시클릭 화합물 및 사용 방법
PE20250663A1 (es) *	2022-02-08	2025-03-04	Theras Inc	Compuestos con estructura en t formada por al menos cuatro ciclos para usar en el tratamiento del cancer y otras indicaciones

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3130633A1 (de) *	1981-08-01	1983-02-17	Basf Ag, 6700 Ludwigshafen	7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
KR100191774B1 (ko) *	1991-04-22	1999-06-15	오스카 아끼히꼬	피라졸로[1,5-알파] 피리미딘 유도체 및 이것을 함유하는 항염증제
US5707997A (en) *	1994-06-21	1998-01-13	Otsuka Pharmaceutical Factory, Inc.	Pyrazolo 1,5-a!pyrimidine derivative
JP3163413B2 (ja) *	1994-06-21	2001-05-08	株式会社大塚製薬工場	鎮痛剤
WO1998010590A1 (fr) *	1996-09-02	1998-03-12	Sony Corporation	Dispositif et procede de transmission d'un signal video
NZ539163A (en) *	2002-09-04	2007-03-30	Schering Corp	Pyrazolo[1,5-a]pyrimidine compounds useful as cyclin dependent kinase (CDK) inhibitors
KR20050057139A (ko) *	2002-09-04	2005-06-16	쉐링 코포레이션	사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘

2005
- 2005-01-20 PE PE2005000080A patent/PE20051089A1/es not_active Application Discontinuation
- 2005-01-20 AR ARP050100208A patent/AR049769A1/es unknown
- 2005-01-21 JP JP2006550056A patent/JP2007519662A/ja active Pending
- 2005-01-21 WO PCT/EP2005/000602 patent/WO2005070431A1/en not_active Ceased
- 2005-01-21 KR KR1020067014683A patent/KR20070009546A/ko not_active Withdrawn
- 2005-01-21 CN CNA2005800030379A patent/CN1909908A/zh active Pending
- 2005-01-21 RU RU2006130003/15A patent/RU2006130003A/ru not_active Application Discontinuation
- 2005-01-21 BR BRPI0507071-6A patent/BRPI0507071A/pt not_active IP Right Cessation
- 2005-01-21 AU AU2005205915A patent/AU2005205915B2/en not_active Ceased
- 2005-01-21 TW TW094101852A patent/TW200528103A/zh unknown
- 2005-01-21 CA CA002552885A patent/CA2552885A1/en not_active Abandoned
- 2005-01-21 EP EP05706961A patent/EP1708710A1/en not_active Withdrawn
2006
- 2006-07-06 IL IL176737A patent/IL176737A0/en unknown
- 2006-07-10 MA MA29182A patent/MA28400B1/fr unknown
- 2006-07-21 EC EC2006006718A patent/ECSP066718A/es unknown
- 2006-07-21 TN TNP2006000226A patent/TNSN06226A1/en unknown
- 2006-08-22 NO NO20063758A patent/NO20063758L/no not_active Application Discontinuation

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102918043A (zh) *	2010-02-19	2013-02-06	诺瓦提斯公司	作为cdk4/6抑制剂的吡咯并嘧啶化合物
CN102918043B (zh) *	2010-02-19	2015-07-29	诺华股份有限公司	作为cdk4/6抑制剂的吡咯并嘧啶化合物
CN103097380A (zh) *	2010-08-09	2013-05-08	株式会社创药分子设计	酪蛋白激酶1δ 及酪蛋白激酶1ε 抑制剂
CN103097380B (zh) *	2010-08-09	2015-06-03	株式会社创药分子设计	酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂
CN105906630A (zh) *	2015-04-06	2016-08-31	四川百利药业有限责任公司	用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物
CN106588893A (zh) *	2016-12-01	2017-04-26	北京万全德众医药生物技术有限公司	维拉佐酮双氧化物的制备
CN109836428A (zh) *	2019-02-27	2019-06-04	华东师范大学	具有免疫抑制活性的吡唑[4,3-d]嘧啶衍生物及用途
CN114751910A (zh) *	2022-05-17	2022-07-15	重庆文理学院	一种可诱导细胞巨泡式死亡的化合物及其制备方法和应用
CN114751910B (zh) *	2022-05-17	2023-02-24	重庆文理学院	一种可诱导细胞巨泡式死亡的化合物及其制备方法和应用
CN117843642A (zh) *	2022-10-09	2024-04-09	麦科萨药业(苏州)有限公司	一种双官能化合物及其用途
CN117843642B (zh) *	2022-10-09	2026-04-10	麦科萨药业(苏州)有限公司	一种双官能化合物及其用途

Also Published As

Publication number	Publication date
IL176737A0 (en)	2006-10-31
CA2552885A1 (en)	2005-08-04
RU2006130003A (ru)	2008-04-10
JP2007519662A (ja)	2007-07-19
AU2005205915A1 (en)	2005-08-04
KR20070009546A (ko)	2007-01-18
WO2005070431A1 (en)	2005-08-04
PE20051089A1 (es)	2006-01-25
EP1708710A1 (en)	2006-10-11
AU2005205915B2 (en)	2009-05-21
ECSP066718A (es)	2006-10-31
MA28400B1 (fr)	2007-01-02
TNSN06226A1 (en)	2007-12-03
TW200528103A (en)	2005-09-01
AR049769A1 (es)	2006-09-06
NO20063758L (no)	2006-10-23
BRPI0507071A (pt)	2007-06-19

Legal Events

Date	Code	Title	Description
2007-02-07	C06	Publication
2007-02-07	PB01	Publication
2007-04-04	C10	Entry into substantive examination
2007-04-04	SE01	Entry into force of request for substantive examination
2012-04-04	C12	Rejection of a patent application after its publication
2012-04-04	RJ01	Rejection of invention patent application after publication	Open date: 20070207

Publication	Publication Date	Title
CN1909908A (zh)	2007-02-07	用于治疗蛋白激酶依赖性疾病的吡唑并[1,5－a]嘧啶－7－基－胺衍生物
US20090099167A1 (en)	2009-04-16	Organic compounds
CN1186324C (zh)	2005-01-26	稠合杂芳基衍生物
CN101228167A (zh)	2008-07-23	作为蛋白激酶抑制剂的吡唑并[1,5-a]嘧啶-7-基-胺衍生物
CN1140269C (zh)	2004-03-03	能够抑制表皮生长因子受体族酪氨酸激酶的双环化合物
CN1538847A (zh)	2004-10-20	4-氨基-6-苯基-吡咯并[2,3-d]嘧啶衍生物
CN101039914A (zh)	2007-09-19	作为激酶抑制剂的三氟甲基取代的苯甲酰胺化合物
CN1655788A (zh)	2005-08-17	治疗蛋白激酶依赖性疾病的1H－咪唑并[4,5－c]喹啉衍生物
CN1863774A (zh)	2006-11-15	用作蛋白激酶抑制剂的化合物和组合物
CN1373763A (zh)	2002-10-09	作为激酶抑制剂的蝶啶酮
CN1922171A (zh)	2007-02-28	嘧啶衍生物
CN101535313A (zh)	2009-09-16	作为蛋白激酶调节剂的3-氨基羰基取代的稠合的吡唑衍生物
CN1902200A (zh)	2007-01-24	用做蛋白激酶抑制剂的1h－咪唑并喹啉类衍生物
CN1230187A (zh)	1999-09-29	作为蛋白质酪氨酸激酶抑制剂的二环杂芳族化合物
CN101098873A (zh)	2008-01-02	作为激酶抑制剂的1,4-取代的吡唑并嘧啶
CN101351467A (zh)	2009-01-21	作为EphB和VEGFR2激酶抑制剂的3-(取代的氨基)-吡唑并[3,4-d]嘧啶类物质
CN1236780A (zh)	1999-12-01	吡唑并嘧啶和吡唑并三嗪
CN1714092A (zh)	2005-12-28	作为蛋白激酶抑制剂的噻吩并[3,2－b]吡啶－6－腈和噻吩并[2,3－b]吡啶－5－腈
CN1292788A (zh)	2001-04-25	作为蛋白酪氨酸激酶抑制剂的二环杂芳族化合物
CN1627944A (zh)	2005-06-15	取代的喹唑啉－4－基胺类似物作为辣椒辣素调节剂
CN1659145A (zh)	2005-08-24	作为egf－r和her2激酶抑制剂的3－氰基喹啉
CN1541208A (zh)	2004-10-27	用作细胞周期蛋白依赖性激酶抑制剂的2-苯氨基-嘧啶衍生物
CN1395578A (zh)	2003-02-05	吡啶并[2,3－d]嘧啶－2,7－二胺激酶抑制剂
CN101031560A (zh)	2007-09-05	用作酪氨酸激酶抑制剂的环状二芳基脲
CN1838959A (zh)	2006-09-27	Erbb2抗癌剂的给药方案